ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer

Benzer Materyaller

• LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
  Yazar:: Emens, L.A., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
  Yazar:: Wang, Hanwen, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
  Yazar:: Franzoi, Maria Alice, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• ESMO presidential symposium wrap up: the ClarIDHy trial
  Yazar:: Abou-Alfa, Ghassan K
  Baskı/Yayın Bilgisi: (2020)
• Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
  Yazar:: Iwata, Hiroji, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)